Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 19, 2026 09:15 ET | Source: Edesa Biotech, Inc.

Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference

Oral presentation at ERA Congress, the flagship European nephrology meetingCompany expects to present additional data TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA),...
May 14, 2026 16:30 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
March 31, 2026 16:20 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
March 26, 2026 09:15 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
February 24, 2026 09:15 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files...
February 13, 2026 16:20 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
December 12, 2025 16:20 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal Year 2025 Results

TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
October 31, 2025 16:30 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Announces Upcoming Conference Schedule

TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
October 28, 2025 07:45 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with clinically meaningful improvement in survival and...
August 08, 2025 16:35 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...